Palvella Therapeutics (PVLA) Total Non-Current Liabilities (2013 - 2026)
Palvella Therapeutics (PVLA) posted quarterly Total Non-Current Liabilities of $19.8 million for Q1 2026, down 10.57% year-over-year from $22.1 million in Q1 2025, and up 11.24% quarter-over-quarter from $17.8 million in Q4 2025.
Palvella Therapeutics (PVLA) Total Non-Current Liabilities (2013 - 2026) Analysis & Trends
Palvella Therapeutics (PVLA) has reported Total Non-Current Liabilities for 14 consecutive years, with $19.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Non-Current Liabilities fell 10.57% year-over-year to $19.8 million; the TTM figure through Mar 2026 stood at $19.8 million (down 10.57% YoY), while the FY2025 annual figure was $17.8 million, up 49.58% from the prior year.
- Total Non-Current Liabilities grew to $19.8 million in Q1 2026 per PVLA's latest filing, from $17.8 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $67.6 million in Q4 2022 and bottomed at $10.4 million in Q4 2023.
- Historically, Total Non-Current Liabilities has averaged $25.2 million across 5 years, with a median of $17.8 million in 2025.
- Annual changes were most pronounced in 2023 — Total Non-Current Liabilities sank 84.59% — and 2025, when it soared 49.58%.
- Palvella Therapeutics' Total Non-Current Liabilities stood at $67.6 million in 2022, then tumbled by 84.59% to $10.4 million in 2023, then climbed by 14.27% to $11.9 million in 2024, then jumped by 49.58% to $17.8 million in 2025, then advanced by 11.24% to $19.8 million in 2026.
- Business Quant data shows PVLA's Total Non-Current Liabilities at $19.8 million in Q1 2026, $17.8 million in Q4 2025, and $16.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 40.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.53 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.88 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.32 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Palvella Therapeutics | 2.25 Bn | 1.93 Bn | - | 22.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 22.10 Mn |
| Mar 31, 2026 | 19.80 Mn |
| Dec 31, 2025 | 17.80 Mn |
| Sep 30, 2025 | 16.00 Mn |
| Jun 30, 2025 | 14.50 Mn |
| Mar 31, 2025 | 22.14 Mn |
| Dec 31, 2024 | 11.90 Mn |
| Dec 31, 2023 | 10.41 Mn |
| Jun 30, 2023 | 47.05 Mn |
| Dec 31, 2022 | 67.56 Mn |
| Dec 31, 2021 | 102.81 Mn |
| Sep 30, 2021 | 110.33 Mn |
| Jun 30, 2021 | 108.31 Mn |
| Mar 31, 2021 | 77.55 Mn |
| Dec 31, 2020 | 73.98 Mn |
| Dec 31, 2019 | 89.75 Mn |
| Sep 30, 2019 | 84.03 Mn |
| Jun 30, 2019 | 99.04 Mn |
| Mar 31, 2019 | 100.86 Mn |
| Dec 31, 2018 | 101.38 Mn |